EN | DE
Researcher in Laboratory © HIPS

Dr Chantal Bader

About

Chantal Bader studied Pharmacy at the Ruprecht-Karls-University Heidelberg, Germany (Approbation as Pharmacist, 2016). In 2016, she the department of Rolf Müller at HIPS. Working on the isolation and characterization of natural products from myxobacteria, she obtained her masters and later on Ph.D. degree here. Supported by the DFG Walter-Benjamin-Fellowship, she moved to the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (Florida, US, 2022), where she joined Prof. Shens group. As leader of function-guided screenings of the extensive extract library here, she expanded her focus towards discovery of anti-Gram-negative antibiotics and antiplasmodials from actinobacteria. In July 2024, Chantal joined HIPS again as pilot of the Young AcademiXX program.

Chantal’s research focuses on elucidation of uncharacterized natural products with emphasis on antiparasitics and their application for the treatment of neglected tropical diseases. She is particularly interested in the ecological context under which these pharmaceutically relevant natural products are produced and deciphering signaling molecules secreted by taxonomically distant organisms to induce their production. For her outstanding achievements as part of her doctorate, she has been awarded by the HZI Sponsors’ Association and the Hans-und-Ruth-Giessen-Foundation, among others.


2024

Discovery of the Pendulisporaceae: An extremotolerant myxobacterial family with distinct sporulation behavior and prolific specialized metabolism

Garcia R, Popoff A, Bader C, Löhr J, Walesch S, Walt C, Boldt J, Bunk B, Haeckl F, Gunesch A, …, Bach T, Müller R (2024)

Chem 10: 1-20DOI: 10.1016/j.chempr.2024.04.019

Elucidation of unusual biosynthesis and DnaN-targeting mode of action of potent anti-tuberculosis antibiotics Mycoplanecins

Fu C, Liu Y, Walt C, Rasheed S, Bader C, Lukat P, Neuber M, Haeckl F, Blankenfeldt W, Kalinina O, Müller R (2024)

Nat Commun 15 (1)DOI: 10.1038/s41467-024-44953-5

2023

Genome-Guided Discovery of the Myxobacterial Thiolactone-Containing Sorangibactins

Gao Y, Walt C, Bader C, Müller R (2023)

ACS chemical biology 18 (4): 924-932DOI: 10.1021/acschembio.3c00063

2022

Darobactins Exhibiting Superior Antibiotic Activity by Cryo-EM Structure Guided Biosynthetic Engineering

Seyfert C, Porten C, Yuan B, Deckarm S, Panter F, Bader C, Coetzee J, Deschner F, Tehrani K, Higgins P, …, Herrmann J, Müller R (2022)

Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202214094

Large-Scale Interlaboratory DI-FT-ICR MS Comparability Study Employing Various Systems

Forcisi S, Moritz F, Thompson C, Kanawati B, Uhl J, Afonso C, Bader C, Barsch A, Boughton B, Chu R, …, Laukien F, Schmitt-Kopplin P (2022)

Journal of the American Society for Mass SpectrometryDOI: 10.1021/jasms.2c00082

Identification and Biochemical Characterization of Pyrrolidinediones as Novel Inhibitors of the Bacterial Enzyme MurA

Fathalla R, Fröhner W, Bader C, Fischer P, Dahlem C, Chatterjee D, Mathea S, Kiemer A, Arthanari H, Müller R, …, Ducho C, Engel M (2022)

Journal of medicinal chemistryDOI: 10.1021/acs.jmedchem.2c01275

Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA-Virus Inhibitors

Haack P, Harmrolfs K, Bader C, Garcia R, Gunesch A, Haid S, Popoff A, Voltz A, Kim H, Bartenschlager R, Pietschmann T, Müller R (2022)

Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202212946

Sandacrabins - Structurally Unique Antiviral RNA Polymerase Inhibitors from a Rare Myxobacterium

Bader C, Panter F, Garcia R, Tchesnokov E, Haid S, Walt C, Spröer C, Kiefer A, Götte M, Overmann J, Pietschmann T, Müller R (2022)

Chem. Eur. J. 28 (10)DOI: 10.1002/chem.202104484

2021

Improved broad-spectrum antibiotics against Gram-negative pathogens via darobactin biosynthetic pathway engineering

Groß S, Panter F, Pogorevc D, Seyfert C, Deckarm S, Bader C, Herrmann J, Müller R (2021)

Chem. Sci. 12 (35): 11882-11893DOI: 10.1039/d1sc02725e

Sesbanimide R, a Novel Cytotoxic Polyketide Produced by Magnetotactic Bacteria

Awal R, Haack P, Bader C, Riese C, Schüler D, Müller R (2021)

mBio 12 (3)DOI: 10.1128/mBio.00591-21

Search for the Active Ingredients from a 2-Aminothiazole DMSO Stock Solution with Antimalarial Activity

Ropponen H, Bader C, Diamanti E, Illarionov B, Rottmann M, Fischer M, Witschel M, Müller R, Hirsch A (2021)

ChemMedChem 16 (13): 2089-2093DOI: 10.1002/cmdc.202100067

Synergizing the potential of bacterial genomics and metabolomics to find novel antibiotics

Panter F, Bader C, Müller R (2021)

Chem. Sci. 12 (17): 5994-6010DOI: 10.1039/d0sc06919a

The Sandarazols are Cryptic and Structurally Unique Plasmid-Encoded Toxins from a Rare Myxobacterium*

Panter F, Bader C, Müller R (2021)

Angewandte Chemie (International ed. in English) 60 (15): 8081-8088DOI: 10.1002/anie.202014671

Expanding the Scope of Detectable Microbial Natural Products by Complementary Analytical Methods and Cultivation Systems

Bader C, Haack P, Panter F, Krug D, Müller R (2021)

Journal of natural products 84 (2): 268-277DOI: 10.1021/acs.jnatprod.0c00942

2020

Supercritical Fluid Extraction Enhances Discovery of Secondary Metabolites from Myxobacteria

Bader C, Neuber M, Panter F, Krug D, Müller R (2020)

Analytical chemistry 92 (23): 15403-15411DOI: 10.1021/acs.analchem.0c02995

In depth natural product discovery - Myxobacterial strains that provided multiple secondary metabolites

Bader C, Panter F, Müller R (2020)

Biotechnol Adv 39DOI: 10.1016/j.biotechadv.2019.107480

2019

Synthesis of New Cyclomarin Derivatives and Their Biological Evaluation towards Mycobacterium Tuberculosis and Plasmodium Falciparum

Kiefer A, Bader C, Held J, Esser A, Rybniker J, Empting M, Müller R, Kazmaier U (2019)

Chem. Eur. J. 25 (37): 8894-8902DOI: 10.1002/chem.201901640

Engineering Atypical Tetracycline Formation in Amycolatopsis sulphurea for the Production of Modified Chelocardin Antibiotics

Lukežic T, Fayad A, Bader C, Harmrolfs K, Bartuli J, Groß S, Lešnik U, Hennessen F, Herrmann J, Pikl Š, Petkovic H, Müller R (2019)

ACS Chem. Biol. 14 (3): 468-477DOI: 10.1021/acschembio.8b01125

2018

Concepts and Methods to Access Novel Antibiotics from Actinomycetes

Hug J, Bader C, Remškar M, Cirnski K, Müller R (2018)

Antibiotics 7 (2)DOI: 10.3390/antibiotics7020044